Yumizen H550
HORIBA ABX SAS · Decision date Sep 14, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 14, 2026 for K260781, the Yumizen H550 submitted by HORIBA ABX SAS of Montpellier, France. The device is an automated differential cell counter under 21 CFR 864.5220, Class II, product code GKZ, in the hematology panel. The submission is a traditional 510(k) for a new device, not a supplement, and the Safety and Effectiveness Summary describes the purpose as clearance for a new device. SESE means clearance to market, not PMA approval.
The stated indications cover classification and enumeration of a listed set of whole-blood parameters, including WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV, RDW-SD, PLT, MPV, and leukocyte subpopulation absolute and percentage counts through IMG%. Specimens are venous blood and capillary blood in K2-EDTA or K3-EDTA, for in vitro diagnostic use in clinical laboratories, with quantitative measurement and qualitative alarm detection. The record does not establish analytical performance, comparative accuracy, or clinical utility; the review document excerpt also references a different model, the Yumizen H2500, so its applicability to this decision is unclear.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Hematology
- Decision date
- Sep 14, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260781
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- HORIBA ABX SAS
- Product code
- GKZ
- Decision code
- SESE
- Decision date
- Sep 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Counter, Differential Cell.
- Applicant
- HORIBA ABX SAS
- Product code
- GKZ
- FDA device class
- 2
FDA decision timeline
K260781 received
Application receipt date recorded by FDA.
K260781 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
HORIBA ABX SAS
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Montpellier
Sources and methodology
- Original FDA record: K260781
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records